ImmunoPET: concept, design, and applications
W Wei, ZT Rosenkrans, J Liu, G Huang, QY Luo… - Chemical …, 2020 - ACS Publications
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …
Bispecific antibodies: a mechanistic review of the pipeline
AF Labrijn, ML Janmaat, JM Reichert… - Nature reviews Drug …, 2019 - nature.com
The term bispecific antibody (bsAb) is used to describe a large family of molecules designed
to recognize two different epitopes or antigens. BsAbs come in many formats, ranging from …
to recognize two different epitopes or antigens. BsAbs come in many formats, ranging from …
Antibody targeting of E3 ubiquitin ligases for receptor degradation
Most current therapies that target plasma membrane receptors function by antagonizing
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
[HTML][HTML] A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to cancer.. For
use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of …
use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of …
The present and future of bispecific antibodies for cancer therapy
Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …
applications that cannot be achieved using conventional IgG-based antibodies …
Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development
M Ovacik, K Lin - Clinical and translational science, 2018 - Wiley Online Library
The tutorial introduces the readers to the fundamentals of antibody pharmacokinetics (PK) in
the context of drug development. Topics covered include an overview of antibody …
the context of drug development. Topics covered include an overview of antibody …
The state of the art of bispecific antibodies for treating human malignancies
S Wang, K Chen, Q Lei, P Ma, AQ Yuan… - EMBO molecular …, 2021 - embopress.org
Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been
extensively explored in translational and clinical studies since they were first developed in …
extensively explored in translational and clinical studies since they were first developed in …
[HTML][HTML] Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their …
D Ellerman - Methods, 2019 - Elsevier
Bispecific molecules redirecting the cytotoxicity of T-cells are a growing class of therapeutics
with numerous molecules being tested in clinical trials. However, it has been a long way …
with numerous molecules being tested in clinical trials. However, it has been a long way …
Overcoming challenges for CD3-bispecific antibody therapy in solid tumors
J Middelburg, K Kemper, P Engelberts, AF Labrijn… - Cancers, 2021 - mdpi.com
Simple Summary CD3-bispecific antibody therapy is a form of immunotherapy that enables
soldier cells of the immune system to recognize and kill tumor cells. This type of therapy is …
soldier cells of the immune system to recognize and kill tumor cells. This type of therapy is …
Bi-specific and tri-specific antibodies-the next big thing in solid tumor therapeutics
K Runcie, DR Budman, V John, N Seetharamu - Molecular Medicine, 2018 - Springer
Antibody-based therapy has revitalized the world of cancer therapeutics since rituximab was
first approved for the treatment of Non-Hodgkin's Lymphoma. Monoclonal antibodies against …
first approved for the treatment of Non-Hodgkin's Lymphoma. Monoclonal antibodies against …